Get the Stockscreener App
16.38
2.44%
0.39
After Hours:
16.38
Syndax Pharmaceuticals Inc stock is traded at $16.38, with a volume of 4.00M.
It is up +2.44% in the last 24 hours and up +19.82% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
See More
Previous Close:
$15.99
Open:
$16.21
24h Volume:
4.00M
Relative Volume:
1.76
Market Cap:
$1.40B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-5.5338
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+9.79%
1M Performance:
+19.82%
6M Performance:
-19.39%
1Y Performance:
-26.32%
1-Day Range:
$16.12
$16.95
1-Week Range:
$14.53
$16.95
52-Week Range:
$12.06
$25.34
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
35 GATEHOUSE DRIVE, WALTHAM, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
16.38 | 1.40B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.7%Here's What Happened - MarketBeat
Should investors be concerned about SNDX’s high price-to-sales ratio? - US Post News
Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Tuesday - MarketBeat
Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation - Yahoo Finance
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
When (SNDX) Moves Investors should Listen - Stock Traders Daily
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth with FDA approvals - Investing.com
Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Insider Sells 4,618 Shares of Stock - MarketBeat
Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells 3,777 Shares of Stock - MarketBeat
Michael A. Metzger Sells 13,288 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Syndax pharmaceuticals CFO Keith Goldan sells $58,558 in stock - MSN
Don't Ignore The Insider Selling In Syndax Pharmaceuticals - Simply Wall St
abrdn plc Takes Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax pharmaceuticals CFO sells $58,558 in stock - MSN
Syndax Pharmaceuticals CEO sells $206,017 in shares - MSN
Syndax pharmaceuticals CFO Keith Goldan sells $58,558 in stock By Investing.com - Investing.com Australia
Syndax pharmaceuticals CFO sells $58,558 in stock By Investing.com - Investing.com Nigeria
Syndax Pharmaceuticals CEO sells $206,017 in shares By Investing.com - Investing.com South Africa
Syndax Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Is Syndax Pharmaceuticals Inc (SNDX) positioned for future growth? - SETE News
2 ‘Strong Buy’ Growth Stocks Poised For 141% To 193% Gains, According To Wall Street - Barchart
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap UpShould You Buy? - MarketBeat
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewswire Inc.
Learn to Evaluate (SNDX) using the Charts - Stock Traders Daily
Syndax Pharmaceuticals Inc [SNDX] stock for 25,037 USD was acquired by Goldan Keith A. - Knox Daily
Syndax Pharmaceuticals Inc (SNDX) deserves deeper analysis - US Post News
Kura Oncology falls despite trial success; rival Syndax gains - Seeking Alpha
Can Syndax Pharmaceuticals Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Syndax Expands Team: Strategic Stock Options Grant Signals Major Growth Phase - StockTitan
Ready to Jump After Recent Trade: Syndax Pharmaceuticals Inc (SNDX) - SETE News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
Syndax Leadership Reveals Growth Strategy at Elite Healthcare Investment Forums - StockTitan
Syndax Announces Participation in February Investor Conferences - Yahoo Finance
(SNDX) Investment Analysis and Advice - Stock Traders Daily
Incyte and Syndax to scale Niktimvo production after FDA approval - BioProcess Insider
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):